Interview, Fireside Chat
Mark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease
- The convergence of AI and biology is projected to yield significant leverage, driving a massive increase in efforts to develop tools that could establish a biological "periodic table" and accelerate basic science to achieve disease prevention and cure goals significantly before the century's end.
- The organization plans to evolve into a singular operating philanthropy centered on the Biohub, which will maintain a 10-to-15-year time horizon for grand challenges while continuing to support education, local communities, and the doubling down on research that has exceeded initial expectations.
- Strategic development includes creating virtual cell models, state-of-the-art protein models, and eventually a virtual immune system to simulate complex systems, with tool development timelines spanning 10 to 15 years and anticipated funding requirements ranging from $100 million to $1 billion.
- Compute infrastructure is expected to expand from 1,000 to 10,000 GPUs to support the "reasoning model" direction, enabling hypothesis generation, precision medicine applications, and the connection of mutations to protein expression for predicting drug side effects.
- A primary expectation is an explosion in community tool deployment for precision medicine, fueled by the ability to treat most diseases as rare due to individual biological differences, thereby allowing others to build diagnostics and therapeutics based on established models.
- The initiative anticipates lower barriers to entry for biological modeling and increased collaboration with external scientists via large-scale compute access, though it acknowledges the need to tolerate early ambiguity while balancing patience with urgency.
- Risks and challenges include the current gaps in biological tools and the necessity for a substantial increase in effort to build tools that can accelerate the entire field effectively.